Paul Feucht

IL-8 induces neutrophil chemotaxis predominantly via type I IL-8 receptors

M. Elizabeth Hammond, Gena Lapointe, Paul Feucht et al. · The Journal of Immunology · 1995 · 372 citations · Full text

Design, Structure−Activity Relationships and in Vivo Characterization of 4-Amino-3-benzimidazol-2-ylhydroquinolin-2-ones: A Novel Class of Receptor Tyrosine Kinase Inhibitors

Paul A. Renhowe, Sabina Pecchi, Cynthia M. Shafer et al. · Journal of Medicinal Chemistry · 2008 · 134 citations · Full text

Pan-PIM Kinase Inhibition Provides a Novel Therapy for Treating Hematologic Cancers

Pablo D. García, John L. Langowski, Yingyun Wang et al. · Clinical Cancer Research · 2014 · 110 citations · Full text

Discovery of Potent and Selective RSK Inhibitors as Biological Probes

Rama Jain, Michelle Mathur, Jiong Lan et al. · Journal of Medicinal Chemistry · 2015 · 82 citations · Full text

Drug Target, Chemoprevention Strategy, Rsk Kinase Family +17

Identification of <i>N</i>-(4-((1<i>R</i>,3<i>S</i>,5<i>S</i>)-3-Amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (PIM447), a Potent and Selective Proviral Insertion Site of Moloney Murine Leukemia (PIM) 1, 2, and 3 Kinase Inhibitor in Clinical Trials for Hematological Malignancies

Matthew T. Burger, Gisele Nishiguchi, Wooseok Han et al. · Journal of Medicinal Chemistry · 2015 · 72 citations · Full text

Hematological Malignancy, Moloney Murine Leukemia, Medicinal Chemistry +14